Carregant...
Use of class I histone deacetylase inhibitor romidepsin in combination regimens
Histone deacetylase (HDAC) inhibitors are epigenetic-modifying agents that have shown promise as anticancer therapies. Several HDAC inhibitors have been approved by the US Food and Drug Administration (FDA) as single-agent therapies to treat T-cell lymphoma. The synergistic combination of HDAC inhib...
Guardat en:
| Publicat a: | Leuk Lymphoma |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4950458/ https://ncbi.nlm.nih.gov/pubmed/27118119 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2016.1160082 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|